← Back to codex

Taurine

Aliases: Taurine

Last verified: 2026-09-23

Clinical trialsModerate evidenceSmall moleculesLow interest

The short version

An aminosulfonic acid — a 2023 Columbia study (Science): lifespan extension in mice/monkeys with age-related decline in levels; drove a surge of longevity research interest. Status: in clinical trials. Legal supplement.

Identity & type

Molecular type
mali molekul
Origin
An aminosulfonic acid — a 2023 Columbia study (Science): lifespan extension in mice/monkeys with age-related decline in levels; drove a surge of longevity research interest.

Mechanism of action

Osmoregulation, calcium modulation, antioxidant, mitochondrial stability.

Dosing & routes

Official / clinical context

No approved official document exists for Taurine. Any protocols mentioned are to be read as information, not as a recommendation.

Regulator-approved labeling and published study designs — never a recommendation.

Community-reported practice

1–6 g/day (trials 1–3 g). One of the best-accepted supplements: fewer cramps, better endurance, calmer cardiovascular response; cheap and safe.

Unverified self-reports. Not medical advice. Not endorsement.

Expected effects (community)

One of the best-accepted supplements: fewer cramps, better endurance, calmer cardiovascular response; cheap and safe.

Protocol — official vs community

Official / label

Supplement. Trials used 1–3 g daily (longevity-association data from the 2023 Science paper; RCTs in metabolic endpoints).

  1. 011–3 g daily

Duration: Continuous.

The animal data (life extension across species) plus human association data make it a longevity-stack staple.

Community (anecdotal)

1–3 g oral daily, morning or around training.

Cycle:
Continuous.
Break:
None.

Energy-drink demonization aside, taurine is one of the best-tolerated compounds in the codex.

Human evidence

Science 2023 preclinical + epidemiology; human RCTs ongoing.

Preclinical evidence

Preclinical literature preceded the clinical trials; details vary by compound.

Known risks

  • Excellent tolerability.characterized

Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.

Unknowns & evidence gaps

  • Long-term safety in off-label use

Frequently asked questions

References

Systematic references are being expanded; verify sources directly before any decision.